AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

2.29

+0.08 (+3.49%)

As of 1:44PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	2.21
Open	2.22
Bid	2.28 x 4000
Ask	2.29 x 800
Day's Range	2.21 - 2.35
52 Week Range	0.63 - 4.24
Volume	1,627,446
Avg. Volume	1,622,234

Market Cap	352.576M
Beta	1.32
PE Ratio (TTM)	N/A
EPS (TTM)	-0.56
Earnings Date	May 11, 2017 - May 12, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	5.67

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks10 days ago
Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
Zacks11 days ago
Why Is AVEO Pharmaceuticals (AVEO) Down 1.6% Since Its Last Earnings Report?
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Business Wire18 days ago
AVEO Oncology to Present at the Jefferies 2018 Healthcare Conference
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need.
ACCESSWIRElast month
Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
Zackslast month
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
GlobeNewswirelast month
Factors of Influence in 2018, Key Indicators and Opportunity within F.N.B., Comcast, IZEA, AVEO Pharmaceuticals, Matador Resources, and TEGNA — New Research Emphasizes Economic Growth
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of F.N.B. ...
Market Exclusivelast month
Here Is What Just Happened With Aveo Pharmaceuticals
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is attracting a substantial amount of attention in the biotechnology space early morning out of Europe this week, with the company moving on and update related to one of its lead development assets in the sector. Here is a look at what happened and why it is important for AVEO and […] The post Here Is What Just Happened With Aveo Pharmaceuticals appeared first on Market Exclusive.
Motley Foollast month
Here's Why AVEO Pharmaceuticals Fell as Much as 17% Today
The company announced a delay concerning its top drug candidate.
Business Wirelast month
AVEO Reports First Quarter 2018 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
Zacks2 months ago
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
Zacks2 months ago
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
Surging implied volatility makes AVEO Pharmaceuticals (AVEO) lucrative to the option traders.
Zacks2 months ago
AVEO Down 7.7% Since Earnings Report: Can It Rebound?
AVEO reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool2 months ago
Why AVEO Oncology Jumped Higher Today
Investors see value after last week's decline.
ACCESSWIRE2 months ago
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Neovasc
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial ...
Zacks2 months ago
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
Business Wire3 months ago
AVEO Oncology to Present at Upcoming Conferences
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
Zacks3 months ago
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
Business Wire3 months ago
AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
AVEO Oncology today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib as second-line treatment in advanced renal cell carcinoma , in the European Journal of Cancer.
Zacks3 months ago
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
Associated Press3 months ago
AVEO posts 4Q profit
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...
Business Wire3 months ago
AVEO Reports Full Year 2017 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the full year ended December 31, 2017 and provided a business update.
Zacks3 months ago
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
Business Wire3 months ago
AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m.
ACCESSWIRE4 months ago
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Exelixis
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / U.S. markets spiked to session highs after minutes from the Fed's January meeting were released, but then dropped as yields for the 10-year Treasury note ...